Question explored with the scientific record
Pneumococcal vaccine for age 64, high blood sugar
The short version: for a 64-year-old with high blood sugar, the pneumococcal vaccine likely cuts your risk of invasive pneumococcal disease, but the evidence on pneumonia is mixed, and the safety data is mostly short-term.
The best evidence for your age group comes from a Spanish study of people 60 and older. The 23-valent polysaccharide vaccine cut invasive pneumococcal disease by 72% overall, and by 77% against the strains it covers [1]. That protection held in people with high-risk conditions like diabetes, with a 71% reduction in that group [1]. But this was a case-control study, not a randomized trial, so it can overstate benefit.
For pneumonia specifically, the picture is weaker. A 2013 Cochrane review found the polysaccharide vaccine did not prevent pneumococcal pneumonia [2]. A 2020 systematic review found protective effects in newer observational studies, but could not pool the results because the studies measured different outcomes [3]. One large Finnish study found no added protection against pneumonia when the vaccine was added to flu shots [4]. The conjugate vaccine (PCV13) did better in one large trial: 46% against pneumococcal pneumonia, 70% against invasive disease [2].
On safety, a 2025 review of over 157,000 adverse event reports found mostly injection-site reactions, with no signal for anaphylaxis or immune disorders [6]. But that system catches only a fraction of real events. A 2018 study found late-onset redness and swelling were common in older adults, affecting about 1 in 5 [5].
| Outcome | Polysaccharide (PPV23) | Conjugate (PCV13) |
|---|---|---|
| Invasive disease | 72% reduction [1] | 70% reduction [2] |
| Pneumococcal pneumonia | Not effective [2] | 46% reduction [2] |
| All-cause pneumonia | Mixed [3][4] | Not shown |
The evidence is mostly observational or funded by the manufacturer, and long-term safety data is thin. For a 64-year-old with high blood sugar, the vaccine likely reduces your risk of serious bloodstream infection, but the benefit for pneumonia is less certain.
My call: reasonable to consider, especially the conjugate vaccine, but the benefit is narrower than advertised. Confidence: moderate.
Sources used 6
-
Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older
In a population-based matched case-control study in Catalonia, Spain, vaccination with 23-valent pneumococcal polysaccharide vaccine was associated with 72% lower adjusted odds of invasive pneumococcal disease (OR 0.28, 95% CI 0.15-0.54) in adults aged 60 years or older.
DOI: 10.1186/1471-2334-10-73 -
Community-acquired pneumonia and pneumococcal vaccination in the elderly
This narrative review describes the epidemiology, etiology, clinical features, and current Canadian recommendations for pneumococcal vaccination against community-acquired pneumonia in the elderly.
DOI: 10.5206/uwomj.v84i2.4296 -
A Systematic Review of Studies Published between 2016 and 2019 on the Effectiveness and Efficacy of Pneumococcal Vaccination on Pneumonia and Invasive Pneumococcal Disease in an Elderly Population
New high-quality observational studies indicate protective VE for PPV23 and PCV13 against vaccine-type pneumonia in elderly populations; PPV23 VE appeared best in younger age groups and decreased over time; no meta-analysis was possible.
DOI: 10.3390/pathogens9040259 -
Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older
A large Finnish prospective cohort study evaluated whether coadministering the 23-valent pneumococcal polysaccharide vaccine with the influenza vaccine provides incremental protection against pneumonia, pneumococcal pneumonia, and pneumococcal bacteraemia in people aged 65 years…
DOI: 10.1016/s0264-410x(99)00069-9 -
Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations
This study investigates the late onset of injection site reactions (ISRs) following vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) in adult populations, revealing that such reactions are more common in older adults and may be influenced by factors such as …
DOI: 10.1080/21645515.2018.1452576 -
Post-marketing safety surveillance of pneumococcal vaccines: a real-world pharmacovigilance study using the U.S. vaccine adverse event reporting system (VAERS) database
Across 157,244 VAERS-reported individuals (632,481 AEs), four-method disproportionality analysis found 929 positive PT signals and 8 positive DME signals, predominantly injection-site/erythema reactions, with no positive signal for anaphylaxis or immune-system disorders.
DOI: 10.3389/fcimb.2025.1635180